Biophytis Publishes Promising Sarcopenia Trial Results

Biophytis SA has announced the publication of its Phase 2 SARA-INT trial results for BIO101 in the Journal of Cachexia, Sarcopenia and Muscle. The clinical-stage biotechnology company focuses on therapies for age-related diseases. The trial demonstrated a clinically meaningful improvement in the 400-meter walk test, highlighting the potential of BIO101 as a treatment for sarcopenia.

The trial results indicate that BIO101 not only improved gait speed in slow walkers and sarcopenic obesity subpopulations but also maintained an excellent safety profile with no serious adverse events. Biophytis is preparing for a Phase 3 trial and is in discussions with pharmaceutical companies in China and Asia.

Sarcopenia affects millions globally, with no current therapeutic solutions. BIO101 positions Biophytis as a leading company in this area, poised to address a growing global health issue.